News: Cancer News

Next Page »« Previous Page

Arteaga Named AACR President-elect

Thursday, March 28th, 2013

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology at Vanderbilt University School of Medicine, has been chosen president-elect for 2013-2014 of the American Association for Cancer Research. Arteaga, who holds the Donna S. Hall Chair in Breast Cancer, also serves as associate director for clinical research and director of the Breast Cancer Research […]

New Fluorescing Agent Helps “Light up” Bladder Cancer

Monday, March 4th, 2013

Two urologic surgeons at Vanderbilt-Ingram Cancer Center are among a leading group of cancer physicians using an innovative new imaging agent and blue light system to “light up” cancerous cells inside the bladder. The combined system is used to confirm non-invasive papillary cancer inside the bladder and help surgeons detect and remove more of the […]

Prostate Cancer Study of Long-term Effects

Thursday, January 31st, 2013

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. The study, led by first author Matthew Resnick, M.D., instructor in Urologic Surgery, Vanderbilt University Medical Center, was […]

U.S. Cancer Death Rates Continue to Drop

Tuesday, January 8th, 2013

Cancer death rates for most forms of cancer have continued to decline in the United States among men and women and all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, (1975-2009). The report, produced since 1988, shows a slow but steady decline in the […]

Lung Cancer Research Gets Boost from Breathe Deep Events

Tuesday, November 13th, 2012

More Tennesseans are expected to die this year from lung cancer than any other form of cancer. Yet, lung cancer research receives far less funding than other forms of the disease. To address this funding disparity, the LUNGevity Foundation will host the second annual Breathe Deep 5-K race/walk event, Saturday, Nov. 17, in Nashville’s Centennial […]

Photo: Lung Cancer Partnership

Friday, September 28th, 2012

Caroline Nebhan, right, a fourth-year student in the M.D./Ph.D. training program, explains a cancer research experiment to advocates from the National Lung Cancer Partnership who toured Vanderbilt-Ingram Cancer Center during their recent meeting in Nashville. Nebhan, who works in the research laboratory of William Pao, M.D., Ph.D., is studying the effects of a specific cancer […]

Target Acquired for Aggressive Tumor

Friday, September 28th, 2012

Angiosarcoma, a rare, aggressive tumor that arises from cells that line blood vessels, has a mortality rate of around 80 percent. Because of their constant contact with the blood stream, these tumors can spread quickly and freely throughout the body. The INK4a/ARF locus on chromosome 9 – a region that encodes tumor suppressor proteins – […]

LifeFlight goes pink for breast cancer awareness

Friday, September 28th, 2012

Nashville (Tenn.) – Vanderbilt LifeFlight is going pink during October to show its support for breast cancer awareness.LifeFlight medical crews will wear a special pink name badge on their flight suits and other staff will wear pink golf shirts. October is designated as National Breast Cancer Awareness Month, dedicated to raising awareness and educating individuals […]

Grant Renewal Boosts GI Cancer Research Program

Friday, September 21st, 2012

Vanderbilt-Ingram Cancer Center’s gastrointestinal Specialized Program of Research Excellence (SPORE) has been awarded its third round of funding by the National Cancer Institute (NCI). “We decided to roll the dice and propose high-risk, high-reward projects,” said Robert Coffey Jr., M.D., Ingram Professor of Cancer Research, professor of Medicine and Cell and Developmental Biology, and director […]

HER2 May Impact Lung Cancer Therapy

Friday, September 21st, 2012

Overcoming therapeutic resistance that inevitably develops is one of the major challenges in treating lung cancer. Non-small cell lung cancers that harbor mutations in the epidermal growth factor receptor (EGFR) are initially responsive to targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs). However, most patients eventually develop resistance to these therapies. One such targeted […]